welcome to DuchenneXchange
- a positively charged Duchenne muscular dystrophy community.- join today!
- log in
Clinical Intramuscular Gene Transfer of rAAV1.CMV.huFollistatin344 Trial to Patients With Duchenne Muscular Dystrophy
study id #: NCT02354781
condition: Duchenne Muscular Dystrophy
status: completed
purpose:The proposed clinical trial is an outgrowth of the safety record and functional improvement seen in the BMD follistatin gene therapy trial. In this study the investigators propose to inject AAV1.CMV.huFS344 at a total dose of 2.4E12 vg/kg to six DMD patients. This dose will be divided between gluteal muscles, quadriceps and tibialis anterior. This is a wider distribution of vector than given to BMD patients, who overall improved the distance walked on the 6MWT without adverse events related to viral transduction into a single muscle.
intervention: rAAV1.CMV.huFollistin344
mechanism of action: Vectored gene therapy to introduce a version of dystrophin
results: https://clinicaltrials.gov/ct2/show/results/NCT02354781
last updated: April 19, 2020
rareRelated
-
First Patient Dosed in Phase II Clinical Trial in Duchenne Muscular DystrophyAntisense Therapeutics today announced d...
-
Catabasis Pharmaceuticals Announces Publication Of Phase 1 Clinical Results Of Edasalonexent (CAT-1004) In Duchenne ...Catabasis Pharmaceuticals, Inc., a clini...
-
SGT-001 improves muscle function of dogs with Duchenne muscular dystrophy, studies showSolid Biosciences’ SGT-001 improved mu...
-
Solid Biosciences Provides SGT-001 Program UpdateCAMBRIDGE, Mass., Nov. 12, 2019 (GLOBE...
-
Microdystrophin Gene Transfer Study in Adolescents and Children With DMDThis is a controlled, open-label, single...
-
Priorities When Deciding on Participation in Early-Phase Gene Therapy Trials for Duchenne Muscular Dystrophy: A Best...Purpose: Several gene therapy trials fo...
-
Phase 2a Extension Study of Ataluren (PTC124) in Duchenne Muscular Dystrophy (DMD)Duchenne muscular dystrophy (DMD) is a g...